Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India Attracts MNC Drug Makers As Vaccine Market Growth Sector

This article was originally published in PharmAsia News

Executive Summary

India is fast becoming attractive to multinational pharmaceutical companies as a place to market vaccines, once relegated to the back burner as among the less-profitable of product lines. GlaxoSmithKline, Novartis and Pfizer are looking at the market potential in India as they see vaccines as one of the more profitable segments of their drug lines. Vaccine sales in India are projected to grow at an annual rate of at least 16 percent, soon becoming a $1 billion market. Three-fifths of the vaccine market in India is pediatric. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts